Lansoprazole Capsule, Delayed Release
Product Images NDC 68071-5119

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lansoprazole (NDC 68071-5119). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 5119 3)

The label for Lansoprazole 30 mg delayed-release capsules from NuCare Pharmaceuticals, Inc. It indicates a quantity of 30 capsules, describes capsule appearance as oblong with a black cap and white body, and includes imprint details. The label includes storage instructions and warnings, along with various barcodes, NDC numbers, lot numbers, and manufacturing details.*

FDA Label Image

F53ca2be-a290-4157-ad95-d24dfe3344f9-01 (F53ca2be A290 4157 Ad95 D24dfe3344f9 01)

Chemical structure of the active ingredient lansoprazole, showing its molecular components including benzene rings, sulfoxide group, and fluoromethoxy substituent.*

FDA Label Image

F53ca2be-a290-4157-ad95-d24dfe3344f9-02 (F53ca2be A290 4157 Ad95 D24dfe3344f9 02)

A line graph showing the mean severity of day heartburn over time from the start of treatment for evaluable patients. The y-axis represents mean severity of day heartburn, scaled from 0 (none) to 3 (severe). The x-axis shows days from start of treatment, ranging from -5 to 60. Three lines represent patient groups: placebo, lansoprazole 15 mg once daily, and lansoprazole 30 mg once daily, indicating changes in heartburn severity over the study period.*

FDA Label Image

F53ca2be-a290-4157-ad95-d24dfe3344f9-03 (F53ca2be A290 4157 Ad95 D24dfe3344f9 03)

A line graph showing the mean severity of night heartburn over days from the start of treatment for evaluable patients. It compares placebo, Lansoprazole 15 mg QD, and Lansoprazole 30 mg QD groups, with severity measured on a scale from 0 (none) to 3 (severe). The graph demonstrates a decrease in severity over time for Lansoprazole groups compared to placebo.*

FDA Label Image

Pdp (F53ca2be A290 4157 Ad95 D24dfe3344f9 7)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.